WO2001016169A3 - COMPOSITIONS A BASE DE LIGAND 5 (RetL5) ET SES UTILISATIONS - Google Patents

COMPOSITIONS A BASE DE LIGAND 5 (RetL5) ET SES UTILISATIONS Download PDF

Info

Publication number
WO2001016169A3
WO2001016169A3 PCT/US2000/024111 US0024111W WO0116169A3 WO 2001016169 A3 WO2001016169 A3 WO 2001016169A3 US 0024111 W US0024111 W US 0024111W WO 0116169 A3 WO0116169 A3 WO 0116169A3
Authority
WO
WIPO (PCT)
Prior art keywords
ret
retl5
nucleic acid
isolated nucleic
acid sequences
Prior art date
Application number
PCT/US2000/024111
Other languages
English (en)
Other versions
WO2001016169A2 (fr
Inventor
Dane Worley
Original Assignee
Biogen Inc
Dane Worley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Dane Worley filed Critical Biogen Inc
Priority to AU71039/00A priority Critical patent/AU7103900A/en
Publication of WO2001016169A2 publication Critical patent/WO2001016169A2/fr
Publication of WO2001016169A3 publication Critical patent/WO2001016169A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne des compositions de Ret Ligand 5 (RetL5) et leurs utilisations. Elle porte sur des séquences isolées d'acides nucléiques et d'acides aminés pour ligands Ret. Les ligands Ret pour lesquels codent les séquences d'acides nucléiques isolées comportent une séquence signal N-terminal hydrophobe, une séquence C-terminal hydrophobe et un motif de couplage phosphatidylinositol glycane. L'invention concerne également des vecteurs et des cellules hôtes renfermant des ligands Ret codés par les séquences isolées d'acides nucléiques.
PCT/US2000/024111 1999-09-01 2000-09-01 COMPOSITIONS A BASE DE LIGAND 5 (RetL5) ET SES UTILISATIONS WO2001016169A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU71039/00A AU7103900A (en) 1999-09-01 2000-09-01 Ret ligand 5 (retl5) compositions and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15202499P 1999-09-01 1999-09-01
US60/152,024 1999-09-01

Publications (2)

Publication Number Publication Date
WO2001016169A2 WO2001016169A2 (fr) 2001-03-08
WO2001016169A3 true WO2001016169A3 (fr) 2001-09-07

Family

ID=22541242

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/024111 WO2001016169A2 (fr) 1999-09-01 2000-09-01 COMPOSITIONS A BASE DE LIGAND 5 (RetL5) ET SES UTILISATIONS

Country Status (2)

Country Link
AU (1) AU7103900A (fr)
WO (1) WO2001016169A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851434B2 (en) 2017-01-18 2023-12-26 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102132405B1 (ko) 2010-05-20 2020-07-09 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
LT3322706T (lt) 2015-07-16 2021-03-10 Array Biopharma, Inc. Pakeistieji pirazolo[1,5-a]piridino junginiai, kaip ret kinazės inhibitoriai
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TW202410896A (zh) 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044356A2 (fr) * 1996-05-08 1997-11-27 Biogen, Inc. Test diagnostique de detection de la schizophrenie faisant appel a de la miacine
WO1999050298A1 (fr) * 1998-03-31 1999-10-07 Millennium Pharmaceuticals, Inc. GFRα-X, NOUVEAU RECEPTEUR DE FACTEUR NEUROTROPHIQUE DERIVE DE CELLULES GLIALES, ET SON UTILISATION
WO2001002557A1 (fr) * 1999-06-29 2001-01-11 Janssen Pharmaceutica N.V. Recepteur de facteurs neurotrophiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044356A2 (fr) * 1996-05-08 1997-11-27 Biogen, Inc. Test diagnostique de detection de la schizophrenie faisant appel a de la miacine
WO1999050298A1 (fr) * 1998-03-31 1999-10-07 Millennium Pharmaceuticals, Inc. GFRα-X, NOUVEAU RECEPTEUR DE FACTEUR NEUROTROPHIQUE DERIVE DE CELLULES GLIALES, ET SON UTILISATION
WO2001002557A1 (fr) * 1999-06-29 2001-01-11 Janssen Pharmaceutica N.V. Recepteur de facteurs neurotrophiques

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AIRAKSINEN M. S.: "Mus musculus mRNA for GDNF family receptor alpha 4,GPI-anchored isoform (Gfra4 gene)", EMBL DATABASE ENTRY MMU276870; ACCESSION NO. AJ276870, 1 May 2000 (2000-05-01), XP002160455 *
BIRREN B. ET AL.: "Homo sapiens chromosome 11, clone RP11-561P16, map 11, WORKING DRAFT SEQUENCE, 21 unordered pieces", EMBL DATABASE ENTRY AC055771; ACCESSION NO. AC055771, 20 April 2000 (2000-04-20), XP002160403 *
GUNN T.M. ET AL.: "Mus musculus recombination breakpoint containing region", EMBL DATABASE ENTRY AF155960; ACCESSION NO. AF155960, 28 July 1999 (1999-07-28), XP002160400 *
HASHIMOTO K. ET AL.: "Mus musculus brain cDNA, clone MNCb-1073 : 5' end", EMBL DATABASE ENTRY AU035938, ACCESSION NO. AU035938, 8 October 1998 (1998-10-08), XP002160401 *
PASINI B. ET AL.: "RET mutations in human disease", TRENDS IN GENETICS, vol. 12, no. 4, 1 April 1996 (1996-04-01), pages 138 - 144, XP004037254, ISSN: 0168-9525 *
ROBERTSON K ET AL: "The GDNF-RET signalling partnership", TRENDS IN GENETICS, vol. 13, no. 1, 1997, pages 1 - 3, XP004015047, ISSN: 0168-9525 *
SYCAMORE N.: "Human DNA sequence from clone RP5-964F7 on chromosome 20 Contains part of a gene for a putative GDNF family alpha 4 protein, the 3' part of a gene for a novel protein (desintegrin and metalloproteinase), ESTs, STSs, GSSs and CpG islands", EMBL DATABASE ENTRY AL356755; ACCESSION NO. AL356755, 23 May 2000 (2000-05-23), XP002160402 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851434B2 (en) 2017-01-18 2023-12-26 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors

Also Published As

Publication number Publication date
AU7103900A (en) 2001-03-26
WO2001016169A2 (fr) 2001-03-08

Similar Documents

Publication Publication Date Title
WO2001016169A3 (fr) COMPOSITIONS A BASE DE LIGAND 5 (RetL5) ET SES UTILISATIONS
WO2001005950A3 (fr) Nouveaux procedes permettant la presentation de (poly)peptides/proteines sur des particules bacteriophages au moyen de liaisons disulfure
WO2005055946A3 (fr) Facteur de stimulation de colonies de granulocytes glycopegyle
WO2005056760A3 (fr) Hormone stimulant le follicule humain glycopegyle
WO1998004702A3 (fr) Proteines, notamment proteines membranaires, d'helicobacter pylori, leur preparation et utilisation
CA2295999A1 (fr) Proteines nik, acides nucleiques et procedes correspondants
EP1717315A3 (fr) Protéines de liaison et récepteurs d'ostéoprotégérine
WO2005055950A3 (fr) Facteur ix glycopegyle
WO1997008325A3 (fr) Laccases de coprin purifiees et acides nucleiques les codant
CA2266319A1 (fr) Molecule d'acide nucleique isolee codant un antigene associe au cancer, l'antigene lui-meme, et leurs utilisations
WO2006031811A3 (fr) Interferon alpha glycopegyle
WO1996034107A3 (fr) Proteines antivirales, sequences d'adn codant pour ces proteines et utilisations
EP1005540A4 (fr) Proteines ikk-beta, acides nucleiques et procedes
AU2001242749A1 (en) Peptide derivative
Murata et al. Amino acid sequence of a basic blue protein from cucumber seedlings
WO2003007689A3 (fr) Compositions et procedes pour l'utilisation d'agents bioactifs derives d'acides sulfates et sulfones
WO2002059293A3 (fr) Methode et compositions de synthese de peptides, de proteines et de peptidomimetiques
EP1005539A4 (fr) PROTEINES IKK-$g(a), ACIDES NUCLEIQUES ET PROCEDES
WO2002066647A3 (fr) Recepteur de cytokine de type 2 et acides nucleiques codant ce recepteur
EP0816490A3 (fr) Prényl diphosphate syntase mutant
EP1212340A4 (fr) 29 proteines associees au cancer humain
EP1023906A4 (fr) Potentialisateur pour anticorps anti-tumeur lymphoide
WO2005041882A3 (fr) Molecules ciblant selectivement le systeme vasculaire de lesions premalignes ou malignes du pancreas et d'autres organes
WO2001000662A3 (fr) Utilisation de polypeptides fgh-8 humains comme agents neurotrophiques
WO2002007740A3 (fr) Toxine de serpent et utilisation en tant qu'agent pharmaceutique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP